Amanta Healthcare Limited reports Q2 & H1 FY27 financial results with revenue growth
Key highlights
- Q2FY27 revenue increased 17.3% YoY to ₹83.13 crore; H1FY27 revenue at ₹151.94 crore
- Q2FY27 EBITDA rose 21.9% YoY to ₹17.95 crore with margin expansion to 21.6%
- Q2FY27 PAT at ₹4.86 crore, up from ₹1.21 crore in Q2FY26; H1FY27 PAT ₹8.17 crore
Why it's rated major development: the year-on-year change is 302% (50% or more)
Figures checked against the filing by a second AI read. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Other capex / expansion filings this fortnight
- NALCO advances ₹30,000 crore Anugola smelter expansion with key approvals
- TPL Plastech Board Approves Sept 2026 Quarter Results; CEO Change Announced
- KSH International reports Q2 results and approves Rs 1,850 million capacity expansion
- KSH International reports Q2 FY27 results; board approves Phase-3 capacity expansion
- Bhilwara Spinners approves quarter ended 30 Sep 2026 results and capacity expansion
- Bhilwara Spinners approves Sept 2026 quarter results and capacity expansion
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.